The numbers from the UK-listed global tobacco company British American Tobacco were notable in two respects. First, it remains a cash machine, as shown below, with the near 5% dividend yield nicely augmented by a continuing share buyback to make full use (and more over the last two years) of the 7%+ free cash flow yield. Net debt may have pushed up to £9bn, due to shareholder returns being in excess of 100% over the last couple of years, but for a £60bn market cap company with such historic cash flow stability this is rather negligible.
The second interesting aspect was the relatively limited extent the negative FX impact hit profitability. Many other consumer names have been hit into flat/negative reported EPS territory by this impact, but not BAT. This is testimony again to the strong pricing in the tobacco model and other aspects such as the accretive share buy back.
I don't own BAT today but below 3000p a share I note it would be trading below x12 EV/ebit. Given the above characteristics that is a valuation point for a defensive and cash generative share I could make worth based on what I see in today's numbers.
During the late January/early February dip I did buy though BAT's global peer Philip Morris International (link here) and the US-centred Altria (link here). For a fully flexible global investor the relative investor should just prefer Philip Morris at prevailing (see below) but frankly the key is to have some general exposure to the space.




No comments:
Post a Comment